Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Results Dual blockade of GDF8 and ActA during GLP-1 RA-induced weight loss in obese mice preserves lean mass while also increasing fat loss To test whether dual blockade of GDF8 and ActA could help attenuate loss of lean mass during GLP-1 RA-induced weight loss, we tested our antibody combination in diet-induced obese (DIO) mice during treatment with the GLP-1 RA semaglutide (approved by the US Food and Drug Administration as a therapeutic for obesity and diabetes with the brand names of Ozempic and Wegovy)
Depending on treatment response and side effects, your dose may need adjustments
Nuestro trato en los pedidos online es personalizado con cada cliente, y nos ponemos a tu disposicin para cualquier consulta o asesoramiento.
It looks at your genes, biochemistry, and lifestyle
Before any inter-batch-effect correction, each batch of raw metabolomics data underwent standardized preprocessing: 1
US$ 22.92
US$ 28.01
US$ 23.70
US$ 29.62
US$ 22.15
US$ 29.72
US$ 26.06
US$ 25.44
